2026-04-21T20:23:28.423Z / 路透社
作者：迪特里希·克瑙特
2026年4月21日 美国东部时间下午8:23 更新于2小时前
美国地区法官玛德琳·考克斯·阿利奥听取普渡制药董事长史蒂夫·米勒代表公司在法庭听证会上认罪，该听证会围绕普渡制药LP旗下成瘾性处方止痛药奥施康定的处理展开，最终敲定与联邦检察官达成的协议，以解决对这家制药商在…… 购买授权，打开新标签页查看更多内容
- 摘要
- 公司新闻
- 法官推迟量刑以留出更多公众参与时间
- 普渡制药资产将划归各州、地方政府及鸦片类药物受害者
- 此次量刑将为破产和解方案推进扫清障碍
纽约4月21日路透电——美国一名联邦法官周二将普渡制药原定的刑事量刑听证会推迟一周，称希望在结案前留出更多公众参与空间，此案涉及该公司对成瘾性鸦片类药物的营销行为。
美国地区法官玛德琳·考克斯·阿利奥原本预计在新泽西州纽瓦克的一场法庭听证会上接受普渡制药2020年的认罪请求，此举本将对该公司处以35亿美元刑事罚款及20亿美元刑事没收金额，因其在助长鸦片类药物泛滥中扮演的角色——自2000年以来，这场泛滥已造成美国超100万人死亡。
通过《每日案卷》新闻简报获取最新法律资讯，一键开启你的晨间阅读。点击此处订阅。
广告 · 滚动继续阅读
阿利奥最初计划通过Zoom线上举行听证会，但在庭审过程中改变决定，将听证会推迟至4月28日，原因是抗议者和普通民众现身法庭，希望参与本次量刑听证会。一名远程参与听证会的女子在法官发言时高呼：“这不是正义！”
“在本次认罪程序中，最应被听取意见的是受害者，”阿利奥表示，“如果公众和受害者希望现场发言，我会予以安排。”
普渡制药未立即回应置评请求。美国司法部也拒绝就此次推迟置评。
广告 · 滚动继续阅读
此次量刑是普渡制药完成破产和解方案前的最后步骤之一，该方案将解散公司，并利用其资产向鸦片类药物危机受害者支付74亿美元赔偿。
原本有8名鸦片类药物危机受害者被安排在听证会上发言，分享他们所经历的痛苦、损失与成瘾经历。部分提交给法庭的发言敦促法官驳回认罪协议，因为该协议让公司所有者和高管免于被起诉。
普渡制药于2020年达成该认罪协议。该公司承认了多项指控：包括积极向医生推销产品，导致这些药物被非法转移使用；通过规避旨在减少非法鸦片类药物使用的管控措施欺骗政府；以及向医生支付回扣以提高鸦片类药物销量。该公司曾在2007年就已承认过刑事指控，当时其承认就奥施康定的成瘾和滥用风险误导医生及联邦监管机构。
根据与司法部达成的协议，大部分刑事罚款将无需缴纳，允许普渡制药将剩余资产用于偿还债权人，主要是各州和地方政府——这些政府不得不承担鸦片类药物泛滥带来的成本与后果。
2019年普渡制药申请破产后，司法部与其达成协议，联邦政府放弃追讨除2.25亿美元之外的全部罚款和罚金，以便普渡制药能够将资产用于向其他鸦片类药物受害者债权人支付赔偿。
大部分普渡制药和解资金将流向各州和地方政府，这些政府已同意将资金用于鸦片类药物治理工作，例如成瘾治疗。普渡制药的所有者——萨克勒家族成员将至少为该破产和解方案出资65亿美元。
普渡制药是近年来众多制药商、分销商、药店运营商及其他机构之一，这些主体近年来 collectively 同意支付约570亿美元，以解决各州和地方政府提起的诉讼及调查，这些诉讼和指控称他们助推了美国这场致命的鸦片类药物成瘾泛滥。
由迪特里希·克瑙特报道；亚历克西亚·加拉姆法尔维与丽莎·舒梅克编辑
我们的准则：汤森路透信任原则，打开新标签页
Purdue Pharma’s $5.5 billion sentencing for opioid charges delayed after victims show up to court
2026-04-21T20:23:28.423Z / Reuters
By Dietrich Knauth
April 21, 2026 8:23 PM UTC Updated 2 hours ago
U.S. District Judge Madeline Cox Arleo listens as Purdue Chairman Steve Miller enters a guilty plea on the company’s behalf during a court hearing over the handling of Purdue Pharma LP’s addictive prescription painkiller OxyContin, capping a deal with federal prosecutors to resolve an investigation into the drugmaker’s role in the… Purchase Licensing Rights, opens new tabRead more
- Summary
- Companies
- Judge postponed sentencing for more public participation
- Purdue assets will go to states, local governments and opioid victims
- Sentencing will clear the way for the bankruptcy settlement to proceed
NEW YORK, April 21 (Reuters) – A federal judge on Tuesday delayed the planned criminal sentencing of Purdue Pharma by one week, saying she wanted to allow more public participation before concluding a criminal case over the company’s marketing of addictive opioid drugs.
U.S. District Judge Madeline Cox Arleo was expected to accept Purdue’s 2020 guilty plea at a court hearing in Newark, New Jersey, which would have imposed a $3.5 billion criminal fine and $2 billion in criminal forfeiture against the company for its role in fueling an opioid epidemic that has claimed more than 1 million lives in the U.S. since 2000.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
Arleo initially scheduled the hearing to occur on Zoom, but changed course during the proceedings and delayed it until April 28 after protesters and members of the public showed up at court to participate in the sentencing hearing. One woman who joined the hearing remotely shouted, “This is not justice!” while the judge was speaking.
“In this plea, the single most important people that should be heard are the victims,” Arleo said. “If the public and victims wish to be heard in person, I’m going to accommodate that.”
Purdue did not immediately respond to a request for comment. The U.S. Department of Justice declined to comment on the delay.
Advertisement · Scroll to continue
The sentencing is one of the last steps before Purdue can complete a bankruptcy settlement that would dissolve the company and use its assets to pay $7.4 billion to those harmed by the opioid crisis.
Eight victims of the opioid crisis were scheduled to speak at the hearing, sharing their personal stories of suffering, loss and addiction. Some of the statements that were filed in court urged the judge to reject a plea deal that let company owners and executives escape prosecution.
Purdue reached the plea deal in 2020. Purdue admitted to charges that it aggressively marketed its products to doctors who were diverting the drugs for illegal use, defrauding the government by avoiding controls meant to reduce illegal opioid use, and paying kickbacks to doctors to boost its opioid sales. The company previously pleaded guilty to criminal charges in 2007, admitting that it misled doctors and federal regulators about OxyContin’s risk of addiction and misuse.
Most of the criminal fines will go unpaid under an agreement with the Justice Department that allows Purdue to direct its remaining assets to repaying creditors, mostly state and local governments, which were left to deal with the cost and consequences of the opioid epidemic.
The federal government waived its right to repayment for all but $225 million of the fines and penalties to allow Purdue to devote its assets to paying other opioid creditors, in the deal the Justice Department reached with Purdue after the company filed for bankruptcy in 2019.
Most of the Purdue settlement money will go to states and local governments, which have agreed to use the money for opioid abatement efforts such as addiction treatment. Purdue’s owners, members of the Sackler family, are contributing at least $6.5 billion to fund the bankruptcy settlement.
Purdue is one of many drug manufacturers, distributors, pharmacy operators and others who have collectively in recent years agreed to pay about $57 billion to resolve lawsuits and investigations by states and local governments accusing them of helping fuel a deadly opioid addiction epidemic in the U.S.
Reporting by Dietrich Knauth; Editing by Alexia Garamfalvi and Lisa Shumaker
Our Standards: The Thomson Reuters Trust Principles., opens new tab
发表回复